Hepatocellular Carcinoma from a Hepatologist's Perspective

Area of Science:

• Hepatology
• Oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with increasing global incidence and mortality rates.
• HCC is strongly associated with chronic liver disease and is projected to become the third leading cause of cancer-related deaths in the US by 2030.

Purpose of the Study:

• To provide a comprehensive overview of hepatocellular carcinoma (HCC) from a hepatologist's viewpoint.
• To cover key aspects including epidemiology, screening, surveillance, diagnosis, and management strategies for HCC.

Main Methods:

• Review of current literature and clinical guidelines on HCC.
• Discussion of diagnostic modalities such as ultrasound, serum α-fetoprotein testing, CT, and MRI.
• Examination of staging systems like the Barcelona Clinic Liver Cancer (BCLC) system.

Main Results:

• Surveillance for high-risk individuals involves 6-month ultrasound and α-fetoprotein testing.
• Diagnostic workup includes contrast-enhanced CT/MRI and potentially liver biopsy for indeterminate findings.
• Treatment strategies are tailored to HCC stage, ranging from curative therapies (resection, transplantation, ablation) to locoregional and systemic treatments.

Conclusions:

• Effective management of HCC requires a multidisciplinary approach, integrating screening, accurate diagnosis, and stage-specific treatment.
• Understanding the epidemiology and risk factors is essential for public health initiatives targeting HCC.
• Continued research and clinical practice advancements are vital to improve outcomes for patients with hepatocellular carcinoma.